Study guide

9.3 Neuromuscular & Peripheral Nerve Disorders

MRCPI in General Medicine Part I Written

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Strategy & Foundation

1.1 MRCPI Part I Format, Scoring & Standard-Setting 1.2 RCPI BST Curriculum & Single-Best-Answer Exam Strategy

2 Chapter 2: Cardiology & Vascular Medicine

2.1 Acute Coronary Syndromes & Stable Angina 2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies 2.3 Heart Failure & Valvular Heart Disease 2.4 Hypertension, Vascular & Pericardial Diseases

3 Chapter 3: Respiratory Medicine

3.1 Asthma, COPD & Airway Diseases 3.2 Pneumonia, Tuberculosis & Respiratory Infections 3.3 Interstitial Lung Disease & Pleural Disorders 3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea

4 Chapter 4: Gastroenterology & Hepatology

4.1 Upper & Lower GI Disorders & Inflammatory Bowel Disease 4.2 Acute & Chronic Liver Disease 4.3 Pancreatitis, Biliary Tract & GI Bleeding 4.4 Malabsorption, GI Motility & Clinical Nutrition

5 Chapter 5: Nephrology & Acid-Base Disorders

5.1 Acute Kidney Injury & Glomerular Diseases 5.2 Chronic Kidney Disease & Renal Replacement Therapy 5.3 Electrolyte Imbalances & Acid-Base Disorders

6 Chapter 6: Endocrinology & Diabetes

6.1 Diabetes Mellitus & Metabolic Complications 6.2 Thyroid & Calcium Disorders 6.3 Adrenal, Pituitary & Endocrine Syndromes

7 Chapter 7: Rheumatology & Clinical Immunology

7.1 Inflammatory Arthritides 7.2 Systemic Autoimmune & Vasculitic Diseases 7.3 Metabolic Bone Disease & Clinical Immunology

8 Chapter 8: Haematology & Medical Oncology

8.1 Anaemias, Haemostasis & Thrombosis 8.2 Leukaemias, Lymphomas & Plasma Cell Disorders 8.3 Medical Oncology & Oncological Emergencies

9 Chapter 9: Neurology & Dermatology

9.1 Stroke & Cerebrovascular Diseases 9.2 Epilepsy, Headache & Movement Disorders 9.3 Neuromuscular & Peripheral Nerve Disorders 9.4 Cutaneous Manifestations of Systemic Disease

10 Chapter 10: Acute Medicine, Critical Care & Geriatrics

10.1 Acute Poisoning & Toxidromes 10.2 Sepsis, Shock & Resuscitation 10.3 Geriatric Syndromes, Frailty & Comprehensive Care

11 Chapter 11: Clinical Pharmacology & Therapeutics

11.1 Pharmacokinetics & Pharmacodynamics 11.2 High-Risk Drug Classes & Prescribing Safety 11.3 Adverse Drug Reactions & Drug Safety

12 Chapter 12: Basic Sciences, Biostatistics & Clinical Ethics

12.1 Applied Cardiovascular & Respiratory Physiology 12.2 Clinical Biochemistry, Molecular Genetics & Microbiology 12.3 Biostatistics, Evidence-Based Medicine & Ethics

9.3 Neuromuscular & Peripheral Nerve Disorders

Key Takeaways Explain This Topic AI

Guillain-Barré syndrome (GBS) characteristically exhibits albuminocytological dissociation on lumbar puncture, defined as an elevated CSF protein concentration (>1.0 g/L) with a normal white cell count (<10 cells/µL), typically appearing after 7-10 days of symptom onset.

In acute GBS, monitoring Forced Vital Capacity (FVC) and Negative Inspiratory Force (NIF) is vital; an FVC <20 mL/kg or NIF weaker than -30 cmH₂O indicates impending respiratory muscle fatigue requiring elective ICU admission and mechanical ventilation.

Myasthenia gravis is associated with an underlying thymic abnormality in 75% of patients (60% thymic hyperplasia, 15% thymoma); CT thorax is mandatory in all newly diagnosed patients, and thymectomy is curative or disease-modifying in anti-AChR positive generalized MG.

Lambert-Eaton myasthenic syndrome (LEMS) is caused by autoantibodies directed against presynaptic voltage-gated calcium channels (VGCC) and is associated with small cell lung cancer (SCLC) in >50-60% of cases.

Riluzole, a glutamate neurotransmission inhibitor, is the only disease-modifying pharmacotherapy for Amyotrophic Lateral Sclerosis (ALS), extending median survival by 2 to 3 months when initiated early in the disease course.

Last updated: July 2026

9.3 Neuromuscular & Peripheral Nerve Disorders

This section reviews the clinical features, diagnostic workup, and treatment paradigms for peripheral neuropathies, Guillain-Barré syndrome, Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, Motor Neurone Disease (ALS), and CSF analysis across neuroinfections for MRCPI General Medicine Part I.

Guillain-Barré Syndrome (GBS)

Guillain-Barré syndrome (Acute Inflammatory Demyelinating Polyradiculoneuropathy - AIDP) is an acute, post-infectious, immune-mediated neuropathy characterized by progressive ascending symmetrical weakness and loss of tendon reflexes.

Pathophysiology & Etiology

  • Antecedent Infections: In 60-70% of cases, symptoms occur 1 to 3 weeks following a gastrointestinal or respiratory infection. The most common pathogen is Campylobacter jejuni (associated with molecular mimicry between bacterial lipooligosaccharides and human peripheral nerve gangliosides). Other triggers include Cytomegalovirus (CMV), Epstein-Barr virus (EBV), Mycoplasma pneumoniae , and Zika virus.
  • Pathogenic Antibodies: Anti-GM1 and anti-GD1a antibodies are strongly linked to the Acute Motor Axonal Neuropathy (AMAN) variant. Anti-GQ1b antibodies are present in >90% of cases of Miller Fisher Syndrome (the triad of Ophthalmoplegia, Ataxia, and Areflexia ).

Clinical Presentation & Workup

  • Symptom Pattern: Ascending, symmetrical muscle weakness starting in the lower limbs, accompanied by paresthesias in the feet and hands. Areflexia or marked hyporeflexia is universal. Autonomic dysfunction occurs in 50% (labile blood pressure, sinus tachycardia, cardiac arrhythmias, paralytic ileus, urinary retention).
  • Cerebrospinal Fluid (CSF) Findings: Lumbar puncture demonstrates classic Albuminocytological Dissociation —an elevated CSF protein level (>1.0 g/L) with a normal CSF white cell count (<10 cells/µL). Note: CSF protein may be normal during the first 7 days of illness.
  • Nerve Conduction Studies (NCS): Demonstrates demyelinating features: delayed distal latencies, marked slowing of conduction velocities, temporal dispersion, and conduction block.
  • Respiratory Function Monitoring: Impending respiratory failure is evaluated by serial bed-side testing of Forced Vital Capacity (FVC) and Negative Inspiratory Force (NIF) every 4-6 hours:
  • FVC <20 mL/kg • NIF weaker than -30 cmH₂O • Peak Expiratory Flow <40% predicted (Any of these findings mandates immediate transfer to the ICU for elective endotracheal intubation and mechanical ventilation).

Management

  • Immunomodulatory Therapy: Intravenous Immunoglobulin (IVIG) at a total dose of 2 g/kg divided over 5 days, OR Plasma Exchange (PLEX) (5 exchanges over 10 days). Both modalities are equally effective.
  • Contraindication: Systemic corticosteroids are ineffective and contraindicated in GBS, as clinical trials demonstrate no benefit and potential worsening of long-term recovery.

Myasthenia Gravis & Lambert-Eaton Myasthenic Syndrome

Myasthenia Gravis (MG) and Lambert-Eaton Myasthenic Syndrome (LEMS) are autoantibody-mediated disorders of the neuromuscular junction (NMJ) requiring distinct therapeutic approaches.

Diagnostic & Clinical Feature Myasthenia Gravis (MG) Lambert-Eaton Myasthenic Syndrome (LEMS)

Pathophysiology Autoantibodies against postsynaptic Acetylcholine Receptors (AChR) (85%) or Muscle-Specific Tyrosine Kinase ( MuSK ) (10-15%). Autoantibodies against presynaptic P/Q-type Voltage-Gated Calcium Channels (VGCC) (90%), reducing ACh release.

Weakness Pattern Fatigable weakness that worsens with repetitive activity and improves with rest. Asymmetric ptosis, diplopia, bulbar weakness, proximal limbs. Proximal lower limb weakness and gait difficulty. Strength improves after brief voluntary muscle contraction (post-exercise facilitation).

Reflexes Deep tendon reflexes are normal and preserved . Deep tendon reflexes are depressed or absent , but reappear following 10 seconds of maximal muscle exertion .

Autonomic Features Absent. Prominent autonomic dysfunction: dry mouth, metallic taste, erectile dysfunction, constipation, sluggish pupillary light reflexes.

Systemic Association Thymic pathology in 75% (60% thymic hyperplasia, 15% Thymoma ). CT thorax mandatory at diagnosis. Small Cell Lung Cancer (SCLC) in >50-60% of cases. CT chest/abdomen/pelvis and PET-CT mandatory.

Electrodiagnosis Repetitive Nerve Stimulation (RNS at 3 Hz) shows decremental CMAP response (>10% drop). Single-fiber EMG shows increased jitter. RNS at high frequency (20-50 Hz) or post-exercise testing shows a dramatic incremental CMAP response (>100-200% increase).

First-Line Pharmacotherapy Pyridostigmine (oral acetylcholinesterase inhibitor 60 mg 4-6 hourly) + immunosuppression (prednisolone, azathioprine). Amifampridine (3,4-Diaminopyridine) to enhance presynaptic ACh release + treatment of underlying SCLC.

Myasthenic Crisis Management: Defined as respiratory failure or severe bulbar dysfunction requiring mechanical ventilation. Treat immediately with IVIG (2 g/kg over 5 days) or Plasma Exchange. Avoid exacerbating drugs: Aminoglycosides (gentamicin), Fluoroquinolones (ciprofloxacin), Macrolides, Beta-blockers, Magnesium sulfate, and Neuromuscular blocking drugs.

Amyotrophic Lateral Sclerosis (ALS / Motor Neurone Disease)

Amyotrophic Lateral Sclerosis (ALS) is a progressive, fatal neurodegenerative disease characterized by simultaneous degeneration of upper motor neurons (UMN) in the motor cortex and lower motor neurons (LMN) in the brainstem and anterior horn of the spinal cord.

• Clinical Sign Combination: The hallmark of ALS is the presence of mixed UMN and LMN signs in the same anatomical segment/limb :

• UMN Signs: Hyperreflexia, spasticity, extensor plantar response (Babinski sign), brisk jaw jerk.

• LMN Signs: Muscle wasting, weakness, fasciculations (especially of the tongue and limb girdle muscles), hyporeflexia.

• Negative Features (Absence of Non-Motor Signs): ALS is a purely motor disorder . There is no sensory loss , no sphincter dysfunction , and no impairment of extraocular eye movements .

• Diagnostic Confirmation: Electromyography (EMG) demonstrates active denervation (fibrillation potentials, positive sharp waves) and chronic reinnervation in at least 3 spinal regions (cervical, thoracic, lumbosacral) or bulbar territory. MRI brain and spine must be performed to exclude compressive radiculomyelopathy or structural brainstem lesions.

• Evidence-Based Management:

Riluzole: A glutamate neurotransmission inhibitor (50 mg twice daily). It is the only approved disease-modifying drug, prolonging median survival by 2 to 3 months .

Non-Invasive Ventilation (NIV / BiPAP): Indicated when FVC falls below 50% predicted or orthopnea develops. NIV significantly prolongs survival and improves quality of life more than any pharmacological agent.

Enteral Nutrition (PEG): Percutaneous endoscopic gastrostomy inserted before FVC falls below 50% to maintain hydration and nutrition in severe bulbar palsy.

Cerebrospinal Fluid (CSF) Diagnostic Framework

Interpretation of lumbar puncture parameters is a core component of MRCPI Part I examinations across neuroinfections and autoimmune neurological disorders.

Neurological Condition Opening Pressure (cmH₂O) CSF Protein (g/L) (Normal: 0.15-0.45) CSF Glucose Ratio (Normal: >0.6 of serum) CSF Cell Count (/µL) & Predominance Pathognomonic / Diagnostic Tests

Acute Bacterial Meningitis Elevated (>30) Markedly elevated (>1.5 - 5.0) Markedly decreased (<0.4; <1.5 mmol/L) Very high (>1,000 - 10,000); Neutrophils (>80%) Positive Gram stain, bacterial multiplex PCR, positive CSF culture.

Viral Meningitis / Encephalitis Normal / Mildly high (15-25) Normal to mildly elevated (0.5 - 1.0) Normal (>0.6) Elevated (50 - 500); Lymphocytes (>90%) Positive viral PCR (e.g., HSV-1/2, Enterovirus, VZV).

Tuberculous Meningitis Elevated (>25) Markedly elevated (>1.0 - 5.0) Markedly decreased (<0.3; <1.5 mmol/L) Moderate (100 - 500); Lymphocytes Acid-fast bacilli stain (Ziehl-Neelsen), GeneXpert MTB/RIF PCR.

Guillain-Barré Syndrome Normal (10-20) Elevated (>1.0 - 3.0) after 7 days Normal (>0.6) Normal (<10); No pleocytosis Albuminocytological dissociation ; absent oligoclonal bands.

Multiple Sclerosis (MS) Normal (10-20) Normal to mildly high (<0.8) Normal (>0.6) Normal or mild pleocytosis (<50); Lymphocytes Intrathecal Oligoclonal Bands (OCBs) present in CSF, absent in serum.